U.S. Court in DC Dismisses FCA Action Against Drug Maker Alleging Off-Label Marketing
- June 05, 2020
The U.S. District Court for the District of Columbia dismissed a whistleblower action under the False Claims Act (FCA) against Vanda Pharmaceuticals, Inc. (Vanda), ruling the allegations failed to meet the “demanding” materiality standard to proceed with an implied certification theory of liability.
ARTICLE TAGS
You must be logged in to access this content.